Silver, A.; Ho, C.; Ye, Q.; Zhang, J.; Janzen, I.; Li, J.; Martin, M.; Wu, L.; Wang, Y.; Lam, S.;
et al. Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Curr. Oncol. 2023, 30, 5546-5559.
https://doi.org/10.3390/curroncol30060419
AMA Style
Silver A, Ho C, Ye Q, Zhang J, Janzen I, Li J, Martin M, Wu L, Wang Y, Lam S,
et al. Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current Oncology. 2023; 30(6):5546-5559.
https://doi.org/10.3390/curroncol30060419
Chicago/Turabian Style
Silver, Ali, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam,
and et al. 2023. "Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years" Current Oncology 30, no. 6: 5546-5559.
https://doi.org/10.3390/curroncol30060419
APA Style
Silver, A., Ho, C., Ye, Q., Zhang, J., Janzen, I., Li, J., Martin, M., Wu, L., Wang, Y., Lam, S., MacAulay, C., Melosky, B., & Yuan, R.
(2023). Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current Oncology, 30(6), 5546-5559.
https://doi.org/10.3390/curroncol30060419
